Application Value of Caprini Risk Assessment Model and Elevated Tumor-specific D-dimer Level in Predicting Postoperative Venous Thromboembolism for Patients Undergoing Surgery of Gynecologic Malignancies
Overview
Affiliations
Aim: Venous thromboembolism (VTE) is a major cause of morbidity and mortality in gynecologic malignant patients after surgery. We aimed to validate the Caprini risk assessment model (RAM) and elevated tumor-specific D-dimer as predictive marker of postoperative VTE for patients undergoing surgery of gynecologic malignancies.
Methods: Inpatients were divided into five groups (low: score = 0-1; moderate: score = 2; high: score = 3-4; higher: score = 5-7; sup-high: score > 7) and treated according to their risk level after the surgery during the hospitalization according to the Caprini RAM. D-dimer level was detected during the perioperative period. If D-dimer did not fall to normal reference range on the seventh day after operation, the use of low-molecular-weight heparin was prolonged to 28 days after surgery.
Results: The majority (853/974, 87.6%) of the patients was in the Caprini score ≥5, with an overall VTE incidence of 1.75%. The VTE group had significantly higher Caprini score, CA125, vascular invasion rate and lymph node metastasis rate. If 1.5 μg/mL was used as the D-dimer cut-off value to predicting VTE, the sensitivity was 87.5%, the specificity was 93.8% and the negative predictive value was 99.2%. The D-dimer level was a marker for prolonging the anticoagulants use during the perioperative period, especially for the sup-high group.
Conclusion: The Caprini RAM is an effective and reliable VTE risk prediction tool for patients undergoing gynecological malignant tumor surgery. The group (score ≥ 5) can be divided into two subgroups (higher: score = 5-7 and sup-high: score > 7), which may better predict the occurrence of VTE for malignant tumor patients. Great than 1.5 μg/mL D-dimer before operation should be given more attention for the presence of VTE.
Mazmanyan D, Zhu R, Gao J, Yang Y, Zhong J, Chen J J Otol. 2024; 19(2):59-62.
PMID: 39720111 PMC: 11665942. DOI: 10.1016/j.joto.2024.01.001.
Sisi Y, Genpeng L, Yao C, Suting S, Rongying T, Jiayi D Cancer Control. 2024; 31:10732748241290767.
PMID: 39428606 PMC: 11497502. DOI: 10.1177/10732748241290767.
A composite risk assessment model for venous thromboembolism.
Lin M, Hayssen H, Mayorga-Carlin M, Sahoo S, Siddiqui T, Jreij G J Vasc Surg Venous Lymphat Disord. 2024; 13(1):101968.
PMID: 39305950 PMC: 11764112. DOI: 10.1016/j.jvsv.2024.101968.
Chen X, Shi H, Chang J, Guo W, Yang Y, Wang Y Clin Appl Thromb Hemost. 2024; 30:10760296241247205.
PMID: 38632943 PMC: 11025444. DOI: 10.1177/10760296241247205.
Xu Y, Xu M, Zheng X, Jin F, Meng B Med Sci Monit. 2023; 29:e942840.
PMID: 38160251 PMC: 10765549. DOI: 10.12659/MSM.942840.